Red cell aplasia in myelodysplastic syndrome

P J Williamson, D G Oscier, A J Bell, T J Hamblin

Abstract

Six cases of red cell aplasia occurring in patients with myelodysplastic syndromes (MDS) showed a diversity of clinical course and prognosis. In some patients red cell aplasia may have represented an evolution of MDS while in others autoimmune destruction of erythroblasts may have been the mechanism. A proliferative phase is seen in many of these patients, the clinical importance of which is uncertain.

Red cell aplasia (RCA) is a rare disorder characterised by a profound reduction in erythroblasts in the bone marrow. It may be a congenital disorder (Diamond–Blackfan syndrome) or acquired in association with an underlying disease. Of the acquired group, the most common disease associations are with thymoma, viral infections (especially parvovirus), connective tissue disorders and malignancy. In many cases it is possible to show that RCA results from humoral or T cell-mediated suppression of erythroid progenitors. Occasional reports have documented the occurrence of RCA in patients with MDS but it is unknown whether RCA has an autoimmune aetiology or whether it is a manifestation of clonal changes in the bone marrow.

Discussion

The clinical course of cases 1–3 differs greatly from that seen in cases 4–6. In cases 1–3 RCA was associated with an increasing percentage of blasts in the marrow. Cases 2 and 3 also had a proliferative phase (rising peripheral blood platelet, neutrophil, and monocyte counts) prior to an increase in blast cells in the marrow. All three patients died within a short time of the development of RCA and increasing blast percentage in the marrow. The mechanism of RCA in these cases is presumably due to an intrinsic defect of maturation and proliferation of erythroid precursors as part of the myelodysplastic disorder.

In cases 4–6 there was no evidence of proliferative or blastic change; in these patients RCA may have a different, and possibly autoimmune, aetiology. This is particularly suggested by case 4 who became transfusion independent after a short course of prednisolone, having had four weekly transfusions for the preceding five months. We did not look for evidence of recent parvovirus infection but the time course of changes in clinical and

Course in six patients with MDS and RCA

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age/sex</th>
<th>At presentation</th>
<th>Subsequently (time from diagnosis)</th>
<th>Clinical outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>82/F</td>
<td>RAEB Blasts 9%  Erythroblasts 10%</td>
<td>(10m) RAEB Blasts 17%  Erythroblasts 1%</td>
<td>Died of sepsis (11m)</td>
</tr>
<tr>
<td>2</td>
<td>78/F</td>
<td>RARS Erythroblasts 34%</td>
<td>(25m) RARS Erythroblasts 34%  RAEB Blasts 8%  Erythroblasts 1%</td>
<td>Died of sepsis (56m)</td>
</tr>
<tr>
<td>3</td>
<td>81/F</td>
<td>CMML Blasts 2%  Erythroblasts &lt; 1%</td>
<td>(2m) CMML Blasts 12%  Erythroblasts 3%</td>
<td>Died of blastic transformation (7m)</td>
</tr>
<tr>
<td>4</td>
<td>74/M</td>
<td>RA Erythroblasts &lt; 1%</td>
<td>(7m) RA Erythroblasts 37%</td>
<td>Transfusion independent following steroid treatment; alive and well (22 + m)</td>
</tr>
<tr>
<td>5</td>
<td>58/F</td>
<td>RA Erythroblasts 1%</td>
<td>(6m) RA Erythroblasts 23%</td>
<td>Remains transfusion dependent; alive and well (28 + m)</td>
</tr>
<tr>
<td>6</td>
<td>87/M</td>
<td>RA Erythroblasts 1%</td>
<td>(5m) RA Erythroblasts 1%</td>
<td>Died of unrelated causes (9m)</td>
</tr>
</tbody>
</table>

RA—refractory anaemia; RAEB—refractory anaemia with excess blasts; RARS—refractory anaemia with ringed sideroblasts; CMML—chronic myelomonocytic leukaemia.
Thrombocytosis is a feature of the 5q-syndrome⁶ (a subgroup within MDS), and many of these patients have a degree of erythroid hypoplasia. It is debatable, however, whether such patients should be considered in the same spectrum of disease as those described above.


**Undifferentiated carcinoma of parotid gland**

J J López, J Alfaro, C Ballestin

**Abstract**

Two cases of undifferentiated carcinomas of the major salivary glands were studied using immunohistochemical techniques. Results showed that this entity was a high grade malignant neoplasm arising from the excretory duct. Despite the undifferentiated appearance multiple immunophenotypes were evident in both cases.

Well defined, undifferentiated carcinomas of salivary glands are fairly uncommon high grade neoplasms.¹ These tumours arise in major salivary glands, mainly in the parotid.² Despite the fact that the light microscopic features are undifferentiated,³ electron microscopic studies have shown glandular or neuroendocrine features in some of them.²

In an attempt to detect differentiating features we recently studied two cases using immunohistochemistry.

**Case reports**

**CASE 1**

A 54 year old man presented with a tumour mass on the left side of his neck. The lesion had grown quickly over two months. Ipsilateral subdigastric lymph node metastases were also detected on physical examination. Lumpectomy and lymphadenectomy were performed. Macroscopically, the tumour measured 6 cm and showed multiple haemorrhagic foci. He died of metastatic disease three months later.

**CASE 2**

A 60 year old man presented with a large, left sided tumour mass on his neck. The tumour measured 12 cm. Bilateral lymph node metastases on the lower neck were detected. Palliative surgical resection was performed. Macroscopically, there were multiple haemorrhagic foci with necrotic areas. Death followed rapidly. A post mortem examination was not performed.

In both cases metastatic disease from skin, lung, and gastrointestinal tract was ruled out as far as possible.

Both tumours were located in the parotid gland, and morphologically, fulfilled the light microscopic criteria of undifferentiated carcinomas of major salivary gland. Small or inter-

**J Clin Pathol** 1991;44:432-433
Red cell aplasia in myelodysplastic syndrome.

P J Williamson, D G Oscier, A J Bell and T J Hamblin

doi: 10.1136/jcp.44.5.431

Updated information and services can be found at:
http://jcp.bmj.com/content/44/5/431

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/